Literature DB >> 24122185

Gray matter damage predicts the accumulation of disability 13 years later in MS.

Massimo Filippi1, Paolo Preziosa, Massimiliano Copetti, Gianna Riccitelli, Mark A Horsfield, Vittorio Martinelli, Giancarlo Comi, Maria A Rocca.   

Abstract

OBJECTIVES: To assess the value of conventional and magnetization transfer (MT) MRI measures of white matter (WM) and gray matter (GM) damage, and their 12-month change, in predicting long-term disability and cognitive impairment in multiple sclerosis (MS).
METHODS: Conventional and MT MRI brain scans were obtained at baseline and at 12 months in 73 patients, who were followed prospectively with clinical visits and rating of the Expanded Disability Status Scale score and the MS severity score (MSSS) for a median period of 13.3 years. At 13-year follow-up, a neuropsychological assessment was also performed when possible. T2-hyperintense and T1-hypointense lesion volumes, GM fraction (GMF), WM fraction, thalamic fraction, average lesion MT ratio (MTR), average GM MTR, average normal-appearing WM MTR, and thalamic MTR were measured. Random forest and multivariable analyses were performed to identify the predictors of neurologic deterioration and cognitive impairment at 13 years.
RESULTS: At 13-year follow-up, 66% of patients showed significant worsening of disability and 37% had worsened cognitively. The multivariable model, in which Expanded Disability Status Scale deterioration at final follow-up was the dependent variable, identified baseline GMF (odds ratio [OR] = 0.79, p = 0.01) as the only predictor of worsening of disability (C-index = 0.69). Baseline disease duration (OR = 1.50, p = 0.08) and average GM MTR (OR = 0.87, p = 0.03) were independent variables associated with cognitive deterioration (C-index = 0.97). Baseline MSSS (β = 0.50, p < 0.0001) and baseline GMF (β = -0.32, p = 0.0005) predicted MSSS at follow-up (r(2) = 0.45).
CONCLUSIONS: GM damage is one of the key factors associated with long-term accumulation of disability and cognitive impairment in MS.

Entities:  

Mesh:

Year:  2013        PMID: 24122185     DOI: 10.1212/01.wnl.0000435551.90824.d0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  54 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.

Authors:  Christian Enzinger; Frederik Barkhof; Olga Ciccarelli; Massimo Filippi; Ludwig Kappos; Maria A Rocca; Stefan Ropele; Àlex Rovira; Torben Schneider; Nicola de Stefano; Hugo Vrenken; Claudia Wheeler-Kingshott; Jens Wuerfel; Franz Fazekas
Journal:  Nat Rev Neurol       Date:  2015-11-03       Impact factor: 42.937

Review 3.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

Review 4.  Preventing disability in inflammatory bowel disease.

Authors:  Patrick B Allen; Corinne Gower-Rousseau; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

Review 5.  Clinical relevance of brain volume measures in multiple sclerosis.

Authors:  Nicola De Stefano; Laura Airas; Nikolaos Grigoriadis; Heinrich P Mattle; Jonathan O'Riordan; Celia Oreja-Guevara; Finn Sellebjerg; Bruno Stankoff; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 6.  Brain MRI atrophy quantification in MS: From methods to clinical application.

Authors:  Maria A Rocca; Marco Battaglini; Ralph H B Benedict; Nicola De Stefano; Jeroen J G Geurts; Roland G Henry; Mark A Horsfield; Mark Jenkinson; Elisabetta Pagani; Massimo Filippi
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

Review 7.  Future Brain and Spinal Cord Volumetric Imaging in the Clinic for Monitoring Treatment Response in MS.

Authors:  Tim Sinnecker; Cristina Granziera; Jens Wuerfel; Regina Schlaeger
Journal:  Curr Treat Options Neurol       Date:  2018-04-20       Impact factor: 3.598

8.  PLXNA3 Variant rs5945430 is Associated with Severe Clinical Course in Male Multiple Sclerosis Patients.

Authors:  Moaz Qureshi; Mohamed Hatem; Raed Alroughani; Sindhu P Jacob; Rabeah Abbas Al-Temaimi
Journal:  Neuromolecular Med       Date:  2017-05-23       Impact factor: 3.843

9.  Multisite reliability and repeatability of an advanced brain MRI protocol.

Authors:  Daniel L Schwartz; Ian Tagge; Katherine Powers; Sinyeob Ahn; Rohit Bakshi; Peter A Calabresi; R Todd Constable; John Grinstead; Roland G Henry; Govind Nair; Nico Papinutto; Daniel Pelletier; Russell Shinohara; Jiwon Oh; Daniel S Reich; Nancy L Sicotte; William D Rooney
Journal:  J Magn Reson Imaging       Date:  2019-01-16       Impact factor: 4.813

10.  Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis.

Authors:  Piotr Sowa; Gro Owren Nygaard; Atle Bjørnerud; Elisabeth Gulowsen Celius; Hanne Flinstad Harbo; Mona Kristiansen Beyer
Journal:  Neuroradiology       Date:  2017-06-05       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.